[go: nahoru, domu]

Jump to content

Roussel Uclaf: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
No edit summary
mNo edit summary
Line 28: Line 28:
| owner =
| owner =
| num_employees =
| num_employees =
| parent = [[Hoechst AG|Hoechst]] [[Schering AG|Schering]] AgrEvo [[Gesellschaft mit beschränkter Haftung|GmBh]] (1994)
| parent = [[Hoechst Schering AgrEvo GmBh]] (1994)
| divisions =
| divisions =
| subsid = Roussel UCLAF Holdings Corporation
| subsid = Roussel UCLAF Holdings Corporation

Revision as of 19:10, 29 October 2009

Roussel-UCLAF S.A.
Company typeS.A. (corporation)
IndustryPharmaceutical
Headquarters,
Number of locations
Paris
Key people
J.P. Godard (Chairman)
O. Jacquesson (Director General)
D. Camus (CFO)
E. Sakiz (Chairman, Supervisory Board)
M. Fruhauf (Vice-Chairman, Supervisory Board)
Productsmifepristone (RU 486)
ParentHoechst Schering AgrEvo GmBh (1994)
SubsidiariesRoussel UCLAF Holdings Corporation
Footnotes / references
[1],[2]

Roussel Uclaf S.A. is a French company, headquartered in Romainville.[1] It is involved in healthcare, agro-chemical, animal health and related fields, although in 1994, many of its non-core activities were transferred to its new parent company, Hoechst Schering AgrEvo GmBh in Germany.[1],[2]

Although it has more than 10,000 patents worldwide,[1] Roussel Uclaf is best known for the abortifacient mifepristone, otherwise known by its laboratory name of RU 486. The US patent rights for this drug were donated to Population Council, Inc., a not-for-profit corporation in the USA, in 1994.[3]

The RU 486 drug involved the corporation in some controversy. In fact, in 1996, the US magazine The Economist reported that Roussel UCLAF considered abandoning the drug altogether.[4]

References

  1. ^ a b c d Business Directory
  2. ^ a b Businessweek profile, October 29, 2009
  3. ^ United States court of appeals, Case #96-1246, January 8, 1997
  4. ^ It embarrasses them. (French pharmaceutical company Roussel Uclaf may abandon its production of the drug RU486 because of its controversial use as an abortion pill). The Economist. March 30, 1996.